一项在骨髓纤维化受试者中评价PI3Kδ抑制剂Parsaclisib联合芦可替尼的III期、随机、双盲、安慰剂对照研究
[Translation] A phase III, randomized, double-blind, placebo-controlled study evaluating the PI3Kδ inhibitor Parsaclisib in combination with ruxolitinib in subjects with myelofibrosis
评价并比较parsaclisib+芦可替尼组与安慰剂+芦可替尼组在第24周的脾脏体积。
[Translation] Spleen volume at week 24 was evaluated and compared in the parsaclisib + ruxolitinib and placebo + ruxolitinib groups.
一项在对芦可替尼反应不佳的骨髓纤维化受试者中评价 PI3Kδ抑制剂 Parsaclisib 联合芦可替尼的随机、双盲、安慰剂对照研究
[Translation] A randomized, double-blind, placebo-controlled study evaluating the combination of the PI3Kδ inhibitor Parsaclisib with ruxolitinib in myelofibrotic subjects who did not respond well to ruxolitinib
评价并比较 parsaclisib+芦可替尼组与安慰剂+芦可替尼组在第 24 周的脾脏体积。
[Translation] Spleen volume at week 24 was evaluated and compared between the parsaclisib+ruxolitinib group and the placebo+ruxolitinib group.
比较Selpercatinib与卡博替尼或凡德他尼治疗进展性、晚期、未经激酶抑制剂治疗、RET突变型甲状腺髓样癌患者的3期试验
[Translation] Phase 3 trial comparing selpercatinib to cabozantinib or vandetanib in patients with advanced, advanced, kinase inhibitor-naïve, RET-mutant medullary thyroid cancer
比较接受LOXO-292治疗与接受卡博替尼或凡德他尼治疗的进展性、晚期、未经激酶抑制剂治疗、RET突变型MTC患者中的TFFS。a:比较接受LOXO-292治疗与接受卡博替尼或凡德他尼治疗的进展性、晚期、未经激酶抑制剂治疗、RET突变型MTC患者中所观察到的其他有效性指标(根据RECIST 1.1标准).b:评价LOXO-292与卡博替尼或凡德他尼相比的安全性和耐受性.c:比较LOXO-292与卡博替尼或凡德他尼的耐受性.
[Translation] To compare TFFS in patients with progressive, advanced, kinase inhibitor-naïve, RET-mutant MTC treated with LOXO-292 versus cabozantinib or vandetanib. a: Comparison of other measures of efficacy observed in patients with progressive, advanced, kinase inhibitor-naïve, RET-mutant MTC treated with LOXO-292 versus cabozantinib or vandetanib (according to RECIST 1.1 Criteria).b: To evaluate the safety and tolerability of LOXO-292 compared to cabozantinib or vandetanib.c: To compare the tolerability of LOXO-292 to cabozantinib or vandetanib .
100 Clinical Results associated with QS Pharma, LLC
0 Patents (Medical) associated with QS Pharma, LLC
100 Deals associated with QS Pharma, LLC
100 Translational Medicine associated with QS Pharma, LLC